



**Earnings Presentation** | Q4FY20







This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section be fore taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company under takes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.

## **Company Overview**





### What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.



Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

## Mission



It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life!

## Vision



Our vision at Advanced Enzymes is to become the largest, enzymebased, value provider to consumers and processors globally!







# **Advanced Enzyme Technologies Limited – A Rising Global Star**






Manufacturing Units – 7

India - 5 USA - 2



R&D Units – 7

India – 4 | USA – 1 | Germany – 2



Note: Facts & Figures as on 31st March 2020



Indian enzyme company



Highest market share in India



Listed integrated enzyme player globally



68+

Registered

**Patents** 

Enzymes & Probiotics



400+

**Proprietary Products** 



700+

Customers Worldwide



2\*

**GRAS** Dossier evaluated by US FDA



45+

Countries Worldwide Presence



550+

**Employees** 



420

 $m^3$ Fermentation Capacity



25+

Years of Fermentation Experience

11

Food Enzyme

Dossiers filed

with EFSA

Note: 2015: as per IGAAP | 2019: as per IndAs








<sup>\*1</sup> GRAS Dossier under evaluation with US FDA




# **Results Summary – Q4FY20 (Consolidated)**











**Revenue Breakup** 

₹ in Million

\*YoY Growth

Animal HC				
<u></u>	Q4FY20	126		
49	Q4FY19	121		






Note: 1. On Consolidated Basis 2. PAT is before minority

3. Segment-wise revenue does not include other operating income and Ind AS adjustments


4. Ind AS adjustments are carried out on account of commission and discount.














<sup>4.</sup> Ind AS adjustments are carried out on account of commission and discount.







Note: 1. On Consolidated Basis 2. PAT is before minority


<sup>3.</sup> Segment-wise revenue does not include other operating income and Ind AS adjustments

# Results Summary – FY20












**Revenue Breakup** 

₹ in Million

\*YoY Growth







Note: 1. On Consolidated Basis

2. PAT is before minority


3. Segment-wise revenue does not include other operating income and Ind AS adjustments


4. Ind AS adjustments are carried out on account of commission and discount.











Note: 1. On Consolidated Basis 2. PAT is before minority

Earnings Presentation | Q4FY20 ------

<sup>4.</sup> Ind AS adjustments are carried out on account of commission and discount.



<sup>3.</sup> Segment-wise revenue does not include other operating income and Ind AS adjustments



# Profit & Loss (Consolidated) – Q4FY20 & FY20



₹ in Million except per share data

Particulars	Q4FY20 Audited	Q3FY20 Unaudited	Q4FY19 Audited	Y-o-Y (%)	FY20 Audited	FY19 Audited	Y-o-Y (%)
Income from Operations	1,103	1,119	1,104	0%	4,440	4,196	6%
Expenses	682	655	659	3%	2,675	2,587	3%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	421	464	445	(5%)	1,765	1,609	10%
Other Income	18	12	26	(31%)	57	50	12%
Profit from ordinary activities before Finance Costs and Exceptional Item	439	476	471	(7%)	1,822	1,659	10%
Finance costs	7	8	6	17%	30	39	(23%)
Profit from ordinary activities before exceptional item and tax	432	468	465	(7%)	1,792	1,620	11%
Profit from ordinary activities before tax	432	468	465	(7%)	1,792	1,620	11%
Tax	105	122	130	(20%)	461	461	0%
Net Profit for the period	327	346	335	(2%)	1,330	1,159	15%
Earnings Per Share	2.80	3.01	2.89		11.58	9.95	



# Balance Sheet (Consolidated) – FY20



₹ in Million

Particulars	FY20 Audited	FY19 Audited
Assets		
Property, plant and equipment	2,042	1,618
Capital work-in-progress	101	105
Intangible assets	646	622
Goodwill	2,941	2,715
Other non-current assets	195	183
Current assets	3,813	2,820
Assets held for sale	48	48
Total Assets	9,786	8,111
Equity And Liabilities		
Equity share capital	223	223
Other equity	8,173	6,565
Non-controlling interest	278	260
Non-current liabilities	461	358
Current liabilities	596	651
Liabilities classified as held for sale	55	54
Total – Equity and Liabilities	9,786	8,111



# **Strong Financial Performance – FY20**







Note: As per IGAAP | FY17, FY18, FY19 – as per IndAs


All numbers are on Consolidated basis


ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax, Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth)


# **Strong Financial Performance – FY20**














Note: As per IGAAP | FY17, FY18 & FY19 – as per IndAs

All numbers are on Consolidated basis

Net working capital days =((Trade receivables + inventories - Trade payables)/ Revenue from operations)\*365 Net Debt = Long term debt + short term debt + current maturities of long term debt - Cash & Cash Equivalent




# **Shareholder Information**





### Stock Data (As on 29th May 2020)

Market Capitalization (₹)	16,738 mn
Shares Outstanding	111.64 mn
Free Float	35.98%
Symbol (NSE/ BSE)	ADVENZYMES / 540025



## Stock Chart (As on 29th May 2020)





Note: Data mentioned in above chart is as on 31st Mar 2020





